Interleukin‐18 levels are associated with disease course in patients with Still's disease treated with IL‐1 inhibitors
Objective To evaluate the prognostic utility of circulating interleukin‐18 (IL‐18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in patients with Still disease (SD) receiving first‐line IL‐1 inhibitors (IL‐1i). Methods We retrosp…